Amgen has announced that the US Food and Drug administration (FDA) has converted the accelerated approval for its blood cancer treatment Blincyto to a full approval.
The approval was based on data from 2 studies of blinatumomab in adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia.
Amgen (AMGN) Announces Full FDA Approval of BLINCYTO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.